SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September. H.C.

SOUTH SAN FRANCISCO, Calif. , Aug. 10, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C.

- CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 -                          - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 - - Management to hold conference call today at 5 p.m.

SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report second quarter financial results on Tuesday, August 8, 2023, after the close of U.S.

SOUTH SAN FRANCISCO, Calif. , July 20, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on July 19, 2023 , the Company granted its recently appointed Senior Vice President, Chief Medical

SOUTH SAN FRANCISCO, Calif. , July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu , M.D., as Chief Medical Officer (CMO). In this role, Dr.

- Financing is expected to extend cash runway into the 2 nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones - - $30 million initial investment and up to $90 million in total potential funding - SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif. , June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will present at the Jefferies

- Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) -                          - IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated

SOUTH SAN FRANCISCO, Calif. , May 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report first quarter financial results on Tuesday, May 9, 2023, after the close of U.S.